Wall Street brokerages predict that Oxford Immunotec Global PLC (NASDAQ:OXFD) will report $25.88 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Oxford Immunotec Global PLC’s earnings. The highest sales estimate is $25.90 million and the lowest is $25.83 million. Oxford Immunotec Global PLC posted sales of $23.71 million during the same quarter last year, which suggests a positive year-over-year growth rate of 9.2%. The firm is scheduled to issue its next earnings report on Tuesday, February 27th.

According to Zacks, analysts expect that Oxford Immunotec Global PLC will report full-year sales of $25.88 million for the current year, with estimates ranging from $103.84 million to $105.20 million. For the next year, analysts expect that the company will post sales of $120.15 million per share, with estimates ranging from $118.80 million to $121.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that cover Oxford Immunotec Global PLC.

A number of brokerages recently commented on OXFD. Zacks Investment Research lowered Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Saturday, November 4th. BTIG Research set a $21.00 price target on Oxford Immunotec Global PLC and gave the company a “buy” rating in a research report on Tuesday, October 31st. Robert W. Baird reiterated a “buy” rating and issued a $20.00 price target on shares of Oxford Immunotec Global PLC in a research report on Wednesday, November 1st. ValuEngine cut Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Finally, Piper Jaffray Companies decreased their target price on Oxford Immunotec Global PLC from $26.00 to $19.00 and set an “overweight” rating on the stock in a report on Tuesday, October 31st. Three investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $19.75.

In other news, CEO Peter Wrighton-Smith sold 55,000 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $16.78, for a total transaction of $922,900.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total value of $40,050.00. Following the sale, the director now directly owns 17,778 shares in the company, valued at approximately $237,336.30. The disclosure for this sale can be found here. Insiders sold 61,000 shares of company stock worth $1,010,410 in the last three months. Insiders own 8.11% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OXFD. American International Group Inc. raised its position in shares of Oxford Immunotec Global PLC by 7.1% during the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock worth $212,000 after purchasing an additional 904 shares during the period. Parkwood LLC grew its holdings in shares of Oxford Immunotec Global PLC by 12.9% during the second quarter. Parkwood LLC now owns 12,799 shares of the company’s stock worth $215,000 after buying an additional 1,465 shares in the last quarter. Voya Investment Management LLC grew its holdings in shares of Oxford Immunotec Global PLC by 16.0% during the second quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after buying an additional 1,845 shares in the last quarter. Alliancebernstein L.P. bought a new position in Oxford Immunotec Global PLC in the second quarter valued at approximately $247,000. Finally, Asymmetry Capital Management L.P. bought a new position in Oxford Immunotec Global PLC in the second quarter valued at approximately $273,000. 78.79% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $25.88 Million” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/14/zacks-brokerages-anticipate-oxford-immunotec-global-plc-oxfd-will-announce-quarterly-sales-of-25-88-million.html.

Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at $13.11 on Tuesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.30 and a current ratio of 4.72. Oxford Immunotec Global PLC has a 1-year low of $12.19 and a 1-year high of $19.51.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global PLC (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.